Boston Scientific Corp. has completed its buyout, worth up to $375 million, of Atritech Inc., a Minnesota maker of medical devices.
The acquisition, first announced in January, called for the Natick-based medical device developer to pay $100 million to buy all outstanding shares of Atritech stock, and up to $275 million more based on Atritech revenue and regulatory achievements through 2015.
Atritech makes the WATCHMAN, a device meant to work in place of anticoagulant drugs to treat patients with atrial fibrillation, who are prone to developing blood clots in an area of the heart known as the left atrial appendage. The device has CE Mark approval in the European Union but has not yet gained approval by the U.S. Food and Drug Administration. A news release from Boston Scientific indicated that WATCHMAN was found to bring a 38 percent risk reduction of stroke, cardiovascular death and systemic embolism, compared to anticoagulants.